Literature DB >> 11955524

Impairing the amphetamine conditioning in rats through the inhibition of hippocampal calcium/calmodulin-dependent protein kinase II activity.

S-E Tan1.   

Abstract

Amphetamine is an addictive drug, possessing reinforcing properties that are believed to be associated with an environmental cue, which resembles a behavioral learning process. This study investigates the role of calcium/calmodulin-dependent protein kinase II (CaM-kinase II) in the acquisition of the amphetamine-produced conditioned place preference (CPP). In Experiment I, rats were trained in an amphetamine-produced (2 mg/kg, i.p.) CPP task. The amphetamine-saline pairing rats spent significantly more time in the box that was associated with the amphetamine injection. Moreover, these rats' hippocampal CaM-kinase II showed significantly higher Ca(2+)-independent activity than that of the controls. In experiment II, the rats received an intra-hippocampal or intra-accumbens injection of specific CaM-kinase II inhibitor (KN-93) or a controlled agent (KN-92) before training in the amphetamine-produced CPP task. The rats receiving the preconditioning intra-hippocampal KN-93 injection showed no amphetamine-produced CPP effect. These results, taken together, indicate that the biological basis of amphetamine-produced place preference behavior might be regulated by the hippocampal CaM-kinase II activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11955524     DOI: 10.1016/s0028-3908(02)00004-7

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  7 in total

Review 1.  Protein kinases and addiction.

Authors:  Anna M Lee; Robert O Messing
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

2.  The reinforcing effects of chronic D-amphetamine and morphine are impaired in a line of memory-deficient mice overexpressing calcineurin.

Authors:  Grazyna Biala; Catalina Betancur; Isabelle M Mansuy; Bruno Giros
Journal:  Eur J Neurosci       Date:  2005-06       Impact factor: 3.386

Review 3.  The role of signaling molecules in reward-related incentive learning.

Authors:  Richard J Beninger; Todor Gerdjikov
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

4.  Beta 2 subunit-containing nicotinic receptors mediate acute nicotine-induced activation of calcium/calmodulin-dependent protein kinase II-dependent pathways in vivo.

Authors:  K J Jackson; C L Walters; M I Damaj
Journal:  J Pharmacol Exp Ther       Date:  2009-05-12       Impact factor: 4.030

5.  αCaMKII autophosphorylation controls the establishment of alcohol drinking behavior.

Authors:  Alanna C Easton; Walter Lucchesi; Anbarasu Lourdusamy; Bernd Lenz; Jalal Solati; Yulia Golub; Piotr Lewczuk; Cathy Fernandes; Sylvane Desrivieres; Ralph R Dawirs; Gunther H Moll; Johannes Kornhuber; Josef Frank; Per Hoffmann; Michael Soyka; Falk Kiefer; Gunter Schumann; K Peter Giese; Christian P Müller; Jens Treutlein; Sven Cichon; Monika Ridinger; Peter Mattheisen; Stefan Herms; Norbert Wodarz; Peter Zill; Wolfgang Maier; Rainald Mössner; Wolfgang Gaebel; Norbert Dahmen; Norbert Scherbaum; Christine Schmäl; Michael Steffens; Susanne Lucae; Marcus Ising; Bertram Müller-Myhsok; Markus M Nöthen; Karl Mann; Marcella Rietschel
Journal:  Neuropsychopharmacology       Date:  2013-03-04       Impact factor: 7.853

6.  In vivo amphetamine action is contingent on αCaMKII.

Authors:  Thomas Steinkellner; Liudmilla Mus; Birgit Eisenrauch; Andreea Constantinescu; Damiana Leo; Lisa Konrad; Mattias Rickhag; Gunnar Sørensen; Evgenia V Efimova; Eryan Kong; Matthäus Willeit; Tatyana D Sotnikova; Oliver Kudlacek; Ulrik Gether; Michael Freissmuth; Daniela D Pollak; Raul R Gainetdinov; Harald H Sitte
Journal:  Neuropsychopharmacology       Date:  2014-05-29       Impact factor: 8.294

7.  Rewarding Social Interaction in Rats Increases CaMKII in the Nucleus Accumbens.

Authors:  Inês M Amaral; Laura Scheffauer; Angelika B Langeder; Alex Hofer; Rana El Rawas
Journal:  Biomedicines       Date:  2021-12-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.